Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and function. Reported prevalence of this geriatric syndrome, differs depending on the definition, the population and the method used to identify sarcopenia. The causes of sarcopenia are multifactorial, and can include genetic influence, immobility or disuse, endocrine factors, inflammation and nutritional deficiencies. These disorders involve an imbalance between anabolic and catabolic pathways that rules muscle mass. Many drugs taken regularly for common conditions may interact with some mechanisms that can alter the balance between protein synthesis and degradation. This may lead to a harmful or a beneficial effect on muscle mass and strength. Widely prescribed drugs could play an important role during the time of onset and development of sarcopenia. In this paper, we reviewed the current understanding of how can drugs contribute positively or negatively on sarcopenia and muscle wasting. We decided to focus this review on oral common drugs, which are usually prescribed in older adults, leaving aside other drugs as hormone therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000448247 | DOI Listing |
Ageing Res Rev
January 2025
Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Department of Geriatrics and Orthopedics, Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address:
Sarcopenia refers to a neuromuscular disease characterized by age-related declines in muscle mass and function. Since Professor Rosenberg first introduced the concept of sarcopenia in 1989, numerous operational paradigms have been proposed, tested, and validated against negative outcomes. The most recent recommendations advocate that dynapenia, or reduced of muscle strength, should be used alongside low muscle mass for the identification of sarcopenia.
View Article and Find Full Text PDFDiabetes Metab Syndr
January 2025
Department of Anthropology, University of Delhi, Delhi, 110007, India; Laboratory of Kinanthropometry, Ergonomics and Physiological Anthropology, Department of Anthropology, University of Delhi, Delhi, 110007, India. Electronic address:
Aims: To assess the prevalence of possible sarcopenia and sarcopenic obesity phenotypes and investigate their association with self-reported diabetes among community-dwelling individuals aged 45 or above.
Methods: Utilizing data from 62,899 individuals in LASI wave-1 (2017-18), the assessment of possible sarcopenia was done on two critical parameters: muscle (handgrip) strength and physical performance (gait speed), following the 2019 guidelines from the Asian working group on sarcopenia (AWGS). BMI, WC, WHR, and WHtR defined sarcopenic obesity phenotypes.
Cancer Epidemiol Biomarkers Prev
January 2025
University of Alabama at Birmingham, Birmingham, AL, United States.
Background: The association between skeletal muscle and adipose tissue (body composition) and early response using positron emission tomography (PET) in pediatric Hodgkin lymphoma (HL) remains unstudied.
Methods: Patients enrolled on Children's Oncology Group studies AHOD0031 (intermediate-risk HL) and AHOD0831 (high-risk HL) with digital abdominal computed tomography (CT) scans at diagnosis and PET scans after 2 cycles (PET2) were included. Two consecutive slices at the third lumbar vertebra were identified and skeletal muscle index (SMI, in cm2/m2) and total adipose tissue index (TATI, in cm2/m2) were calculated using sliceOmatic (Magog, Canada) and height at diagnosis.
J Hum Nutr Diet
February 2025
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Background: Meeting protein intake recommendations is relevant for maintaining muscle mass. This study aimed to describe protein intake and its association with meal patterns and dietary patterns.
Methods: An in-house designed, web-based 4-day record was used in the national dietary survey (in 2010/2011).
J Cachexia Sarcopenia Muscle
February 2025
Center for Health Information Partnerships, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and disability-free, hospitalization-free and overall survival of cancer patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!